Hemophilia A or B Treatment Study

Clinical Trial Title

A phase 1/2a, open-label, multicenter, dose escalation study to assess the safety, pharmacokinetics and pharmacodynamics profile of a long-acting recombinant Factor VIIa (MOD-5014) in adult men with hemophilia A or B, with or without inhibitors.

Contact Information

Lisa Boggio, MD

Clinical Trial Protocol Description:

This study will consist of 3 time periods: a screening period of up to 28 days, 1 day of drug administration and 29 days of follow-up.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have moderate to severe hemophilia A or B.
  • Are male at least 18 yeras of age.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Lisa Boggio, MD

Contact Information

Lisa Boggio, MD

(312) 942-3034

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more